Breaking News

China October Manufacturing PMI 50.8; Est. 51.2
Tweet TWEET

Complete Genomics Announces Court's Favorable Ruling in Patent Litigation Against Illumina, Inc.

Complete Genomics Announces Court's Favorable Ruling in Patent Litigation
Against Illumina, Inc.

MOUNTAIN VIEW, Calif., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Complete Genomics,
Inc. (Nasdaq:GNOM) today announced that Magistrate Judge Elizabeth D. Laporte
of the U.S. District Court for the Northern District of California issued an
Order granting Complete's Motion for Partial Summary Judgment of invalidity in
the patent infringement lawsuit filed against Complete by Illumina, Inc. In
that lawsuit, filed in August 2010, Illumina alleges that Complete infringes
U.S. Patent No. 6,306,597.

In her October 16, 2012 Order, Judge Laporte declared that Claim 1 and
dependent Claims 9, 10, 14, 15, 16, 17, 18 and 19 of Illumina's '597 patent
are all invalid due to prior art.

"We are very pleased that the Court agreed with the position we have
maintained from the commencement of this litigation, that the primary claims
in Illumina's '597 patent are invalid," said Dr. Clifford Reid, Complete's
Chairman, President and Chief Executive Officer.

Illumina's only remaining allegation in the lawsuit is that Complete infringes
Claims 2, 4 and 5 of the '597 patent.Given the Court's prior claim
construction order, Complete strongly believes that it does not infringe these
Claims and intends to continue to vigorously defend itself.

About Complete Genomics

Through its pioneering sequencing-as-a-service model, Complete Genomics
provides the most accurate whole human genomes available today. The ease of
use and power of Complete's advanced informatics and analysis systems provide
genomic information needed to better understand the prevention, diagnosis, and
treatment of diseases. Additional information can be found at
http://www.completegenomics.com.

Caution Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, each as amended, including statements
regarding the remaining claims in this litigation.These forward-looking
statements are based on management's current expectations, are not guarantees
of future performance, and involve certain risks and uncertainties that could
cause actual results to differ materially from management's current
expectations and these forward looking statements.These risk and
uncertainties include, but are not limited to, the unpredictable nature of
litigation, as well as other risks detailed in our most recent Annual Report
on Form 10-K (filed with the SEC on March 9, 2012) and our most recent
Quarterly Report on Form 10-Q (filed with the SEC on August 9, 2012).We
disclaim any obligation to update information contained in our forward-looking
statements, whether as a result of new information, future events or
otherwise.

CONTACT: Complete Genomics, Inc.
         Scott Sandler
         Investor Relations
         (650) 943-2788
         ssandler@completegenomics.com
 
Press spacebar to pause and continue. Press esc to stop.